171 related articles for article (PubMed ID: 14760324)
1. Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy.
James SK; Siegbahn A; Armstrong P; Barnathan E; Califf R; Simoons ML; Wallentin L
Am Heart J; 2004 Feb; 147(2):267-74. PubMed ID: 14760324
[TBL] [Abstract][Full Text] [Related]
2. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.
Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Pieper K; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
Am Heart J; 2001 Nov; 142(5):790-8. PubMed ID: 11685164
[TBL] [Abstract][Full Text] [Related]
3. An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease.
James SK; Oldgren J; Lindbäck J; Johnston N; Siegbahn A; Wallentin L
Am Heart J; 2005 Apr; 149(4):619-26. PubMed ID: 15990743
[TBL] [Abstract][Full Text] [Related]
4. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
Am Heart J; 2003 Feb; 145(2):e6. PubMed ID: 12595861
[TBL] [Abstract][Full Text] [Related]
5. Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease.
Oldgren J; Fellenius C; Boman K; Jansson JH; Nilsson TK; Wallentin L; Siegbahn A
J Intern Med; 2005 Nov; 258(5):420-7. PubMed ID: 16238677
[TBL] [Abstract][Full Text] [Related]
6. Effect of Abciximab on prothrombin activation and thrombin generation in acute coronary syndromes without ST-segment elevation: Global Utilization of Strategies to Open Occluded Coronary Arteries Trial IV in Acute Coronary Syndromes (GUSTO IV ACS) Italian Hematologic Substudy.
Merlini PA; Repetto A; Lombardi A; Vetrano A; Fetiveau R; Cavallini C; Sappè D; Salvioni A; Canziani R; Savonitto S; Mannucci PM; Ardissino D
Circulation; 2002 Feb; 105(8):928-32. PubMed ID: 11864920
[TBL] [Abstract][Full Text] [Related]
7. Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial.
Ottervanger JP; Armstrong P; Barnathan ES; Boersma E; Cooper JS; Ohman EM; James S; Topol E; Wallentin L; Simoons ML;
Circulation; 2003 Jan; 107(3):437-42. PubMed ID: 12551868
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes.
James S; Armstrong P; Califf R; Husted S; Kontny F; Niemminen M; Pfisterer M; Simoons ML; Wallentin L
Eur Heart J; 2002 Oct; 23(19):1538-45. PubMed ID: 12242074
[TBL] [Abstract][Full Text] [Related]
9. Coagulation, inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparin.
James S
Ups J Med Sci; 2004; 109(2):71-122. PubMed ID: 15259448
[TBL] [Abstract][Full Text] [Related]
10. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
Oldgren J; Johnston N; Siegbahn A
Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482
[TBL] [Abstract][Full Text] [Related]
11. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.
Hamm CW; Heeschen C; Goldmann B; Vahanian A; Adgey J; Miguel CM; Rutsch W; Berger J; Kootstra J; Simoons ML
N Engl J Med; 1999 May; 340(21):1623-9. PubMed ID: 10341274
[TBL] [Abstract][Full Text] [Related]
12. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy.
James SK; Lindahl B; Siegbahn A; Stridsberg M; Venge P; Armstrong P; Barnathan ES; Califf R; Topol EJ; Simoons ML; Wallentin L
Circulation; 2003 Jul; 108(3):275-81. PubMed ID: 12847065
[TBL] [Abstract][Full Text] [Related]
13. Soluble CD40 ligand in acute coronary syndromes.
Heeschen C; Dimmeler S; Hamm CW; van den Brand MJ; Boersma E; Zeiher AM; Simoons ML;
N Engl J Med; 2003 Mar; 348(12):1104-11. PubMed ID: 12646667
[TBL] [Abstract][Full Text] [Related]
14. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
Lenderink T; Boersma E; Ruzyllo W; Widimsky P; Ohman EM; Armstrong PW; Wallentin L; Simoons ML;
Am Heart J; 2004 May; 147(5):865-73. PubMed ID: 15131544
[TBL] [Abstract][Full Text] [Related]
15. Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream TIrofiban, in cath Lab Downstream Abciximab (CLOTILDA) study.
Leoncini M; Toso A; Maioli M; Bellandi F; Badia T; Politi A; De Servi S; Dabizzi RP
Am Heart J; 2005 Sep; 150(3):401. PubMed ID: 16169315
[TBL] [Abstract][Full Text] [Related]
16. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
[TBL] [Abstract][Full Text] [Related]
17. Comparative short-term prognostic value of hemostatic and inflammatory markers in patients with non-ST elevation acute coronary syndromes.
Passoni F; Morelli B; Seveso G; Lazzati L; Beria G; Del Rosso G; D'Urbano M; Cafiero F; Mariani G; De Servi S
Ital Heart J; 2002 Jan; 3(1):28-33. PubMed ID: 11899586
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty.
Chen YH; Chen JW; Wu TC; Ding PY; Wang SP; Chang MS
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jan; 63(1):8-15. PubMed ID: 10645045
[TBL] [Abstract][Full Text] [Related]
19. Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
Zahn R; Haubelt H; Bechtloff S; Schneider S; Frilling B; Rustige J; Marsalek P; Seidl K; Senges J; Hellstern P
Herz; 2003 Aug; 28(5):445-52. PubMed ID: 12928744
[TBL] [Abstract][Full Text] [Related]
20. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention.
Saltzman AJ; Mehran R; Hooper WC; Moses JW; Weisz G; Collins MB; Lansky AJ; Kreps EM; Leon MB; Stone GW; Dangas G
J Invasive Cardiol; 2010 Jan; 22(1):2-6. PubMed ID: 20048389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
